Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): August 10,
2018
INNOVUS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
|
8845 Rehco Road, San Diego, CA
|
|
92122
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 249-7873
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR
240.13e-4(c))
|
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 8.01 – Other Events
On August 10, 2018, the Company issued a press release announcing
that it had entered into a purchase agreement with Showcase, a
Canadian company for the purchase of its product
Apeaz® for sale in its 110 stores in the U.S. and
Canada.
The
full text of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
Item 9.01 -- Financial Statements and Exhibits
(d) Exhibits
|
Exhibit
No.
|
Description
|
|
|
Press release
issued August 10, 2018.
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned hereunto duly
authorized.
|
Date: August 10, 2018
|
By:
|
/s/ Randy Berholtz
|
|
|
|
|
Randy
Berholtz
Executive Vice
President, Corporate Development
and General
Counsel
|
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
|
|
Press release
issued August 10, 2018.
|
|
|
|